MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer's disease.
Sriram BalusuKatrien HorréNicola ThruppKatleen CraessaertsAn SnellinxLutgarde SerneelsDries T'SyenIordana ChrysidouAmaia M ArranzAnnerieke SierksmaJoel SimrénJonathan M SchottHenrik ZetterbergWei-Ting ChenDietmar Rudolf ThalEvgenia SaltaMark FiersBart De StrooperPublished in: Science (New York, N.Y.) (2023)
Neuronal cell loss is a defining feature of Alzheimer's disease (AD), but the underlying mechanisms remain unclear. We xenografted human or mouse neurons into the brain of a mouse model of AD. Only human neurons displayed tangles, Gallyas silver staining, granulovacuolar neurodegeneration (GVD), phosphorylated tau blood biomarkers, and considerable neuronal cell loss. The long noncoding RNA MEG3 was strongly up-regulated in human neurons . This neuron-specific long noncoding RNA is also up-regulated in AD patients. MEG3 expression alone was sufficient to induce necroptosis in human neurons in vitro. Down-regulation of MEG3 and inhibition of necroptosis using pharmacological or genetic manipulation of receptor-interacting protein kinase 1 (RIPK1), RIPK3, or mixed lineage kinase domain-like protein (MLKL) rescued neuronal cell loss in xenografted human neurons. This model suggests potential therapeutic approaches for AD and reveals a human-specific vulnerability to AD.
Keyphrases
- endothelial cells
- long noncoding rna
- induced pluripotent stem cells
- pluripotent stem cells
- spinal cord
- single cell
- stem cells
- gold nanoparticles
- resting state
- chronic kidney disease
- multiple sclerosis
- dna methylation
- end stage renal disease
- gene expression
- poor prognosis
- ejection fraction
- cognitive decline
- spinal cord injury
- prognostic factors
- genome wide
- mesenchymal stem cells
- functional connectivity
- patient reported outcomes
- silver nanoparticles